logo BDSP

Base documentaire

  1. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up.

    Article - En anglais

    A two-dose vaccination program against measles, mumps, and rubella (MMR) viruses was started in Finland in 1982.

    In this program the trivalent MMR-II vaccine (MSD, USA) was offered to children at the ages of 14-18 months and 6 years followed by revaccination 4-5 years later.

    The vaccination coverage has been high (97%) and MMR infections have practically been eliminated in the Finnish population.

    In a serological follow-up program sequential serum samples were obtained from 254 children (127 14-18-month-old vaccinees and 127 6-year-old vaccinees) during a 9-year follow-up period.

    Anti-mumps virus antibody titers were determined by enzyme immunoassay using purified whole mumps viruses as the antigen.

    In seronegative (n=120) 14-18-month-old vaccinees the seroconversion rate was 86% (geometric mean titer 1/1670 ± 1/270).

    The antibody levels fell rapidly (significance p<0.01) within the first year of follow-up (mean titer 1/1080 ± 1/190), but remained relatively stable in subsequent years.

    After revaccination the seropositivity rate was 95% (mean titer 1/2310 ± 1/260) and declined more slowly thereafter to 86% (mean titer 1/1510 ± 1/210) at year 9 of follow-up.

    The mean antibody titer was significantly (p<0.05) higher 4 years after the second MMR vaccination when compared with the corresponding time point after the first vaccination.

    In 6-year-old seronegative vaccinees the increase and decay of anti-mumps virus antibodies after the first MMR vaccination was s...

    Mots-clés Pascal : Paramyxovirus ourlien, Paramyxovirus, Paramyxoviridae, Virus, Oreillons, Virose, Infection, Vaccination, Réponse immune, Immunité humorale, Anticorps, Sérologie, Etude longitudinale, Enfant, Homme, Finlande, Europe

    Mots-clés Pascal anglais : Mumps paramyxovirus, Paramyxovirus, Paramyxoviridae, Virus, Mumps, Viral disease, Infection, Vaccination, Immune response, Humoral immunity, Antibody, Serology, Follow up study, Child, Human, Finland, Europe

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0186587

    Code Inist : 002A05C07. Création : 199608.